AP NEWS

Revance to Participate in the UBS Global Healthcare Conference

May 15, 2018

NEWARK, Calif.--(BUSINESS WIRE)--May 15, 2018--Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the Company will participate in the UBS Global Healthcare Conference in New York, NY.

Chief Financial Officer and Chief Business Officer, Lauren Silvernail, is scheduled to present on Tuesday, May 22 at 11:00am ET.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at  www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About Revance Therapeutics, Inc.

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company’s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis, with plans to initiate studies in upper limb spasticity and chronic migraine. RT002 has the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA. More information on Revance may be found at www.revance.com.“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180515005135/en/

CONTACT: INVESTORS

Revance Therapeutics, Inc.:

Jeanie Herbert

(714) 325-3584

jherbert@revance.com

or

Burns McClellan, Inc.:

Ami Bavishi

(212) 213-0006

abavishi@burnsmc.com

or

MEDIA

General Media:

TOGORUN:

Mariann Caprino

(917) 242-1087

m.caprino@togorun.com

or

Trade Media:

Nadine Tosk

(504) 453-8344

nadinepr@gmail.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL OTHER HEALTH RESEARCH OTHER SCIENCE SCIENCE

SOURCE: Revance Therapeutics, Inc.

Copyright Business Wire 2018.

PUB: 05/15/2018 04:05 PM/DISC: 05/15/2018 04:05 PM

http://www.businesswire.com/news/home/20180515005135/en

AP RADIO
Update hourly